[
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2026",
    "title": "Kvartalsrapport Q2 2026",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a0680c241d076247be055e08da27e968d",
    "date": "2026-07-14",
    "period": "2026-q2",
    "form_type": "interim-report",
    "report_key": "2026:q2",
    "filename": "XVIVO_Delarsrapport_Januari_Juni_2026.pdf",
    "text_chars": 79405,
    "sha256": "8bffac95165c5c8b26a6ba714b0d207045823072c1bdc2848938ba7a2f567499",
    "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q2-2026",
    "absolute_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q2-2026",
    "txt_url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q2-2026/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q2-2026/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q2-2026/part-001.html",
        "chars": 79405
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2026",
    "title": "Kvartalsrapport Q1 2026",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a941583dc581b0dbcdcc0aea16c08ba15",
    "date": "2026-04-24",
    "period": "2026-q1",
    "form_type": "interim-report",
    "report_key": "2026:q1",
    "filename": "XVIVO_Delarsrapport_Q1_2026.pdf",
    "text_chars": 68483,
    "sha256": "078f9acc5643a946b13bcf798e7c5bdb9f62511784342e23069ab0140b8888ce",
    "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
    "absolute_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
    "txt_url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q1-2026/part-001.html",
        "chars": 68483
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-arsredovisning-2025",
    "title": "Årsredovisning 2025",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a615f74af236f4a6f9efc8f84ec007fd2",
    "date": "2026-04-01",
    "period": "2025-annual",
    "form_type": "annual-report",
    "report_key": "2025:annual",
    "filename": "XVIVO_Perfusion_Ab_publ_Arsredovisning_2025.pdf",
    "text_chars": 297663,
    "sha256": "32699933fab9b80e4730f5b5cbafc1a712cdd995bc233a139d2d379038636a3d",
    "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-arsredovisning-2025",
    "absolute_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-arsredovisning-2025",
    "txt_url": "/company/xvivo-perfusion/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-arsredovisning-2025/part-001.html",
        "chars": 179473
      },
      {
        "number": 2,
        "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-arsredovisning-2025/part-002.html",
        "chars": 118188
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2025",
    "title": "Kvartalsrapport Q4 2025",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/aab3317c3c213f82c4959f115aec7047b",
    "date": "2026-01-27",
    "period": "2025-q4",
    "form_type": "year-end-report",
    "report_key": "2025:q4",
    "filename": "XVIVO_Bokslutskommunike_2025.pdf",
    "text_chars": 84932,
    "sha256": "be70920de31e7ac3a3e270360657c3be51e0ce8aff4d9076895aaafd02388adf",
    "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
    "absolute_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
    "txt_url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q4-2025/part-001.html",
        "chars": 84932
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2025",
    "title": "Kvartalsrapport Q3 2025",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a6083fd0d00915dbdf5eb7c7061d09e71",
    "date": "2025-10-23",
    "period": "2025-q3",
    "form_type": "interim-report",
    "report_key": "2025:q3",
    "filename": "XVIVO_Delarsrapport_Q3_2025.pdf",
    "text_chars": 88291,
    "sha256": "4c2f06df608966130ce293f0bf24c6ded2a92cdad0c28e048797bd1fc616aaf2",
    "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
    "absolute_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
    "txt_url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q3-2025/part-001.html",
        "chars": 88291
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2025",
    "title": "Kvartalsrapport Q2 2025",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/ac2517d0001a6275598b4a18f26df418f",
    "date": "2025-07-11",
    "period": "2025-q2",
    "form_type": "interim-report",
    "report_key": "2025:q2",
    "filename": "XVIVO_Delarsrapport_Q2_2025.pdf",
    "text_chars": 83790,
    "sha256": "9ca6c576f22c5d350885f34533cf2db39c3cd319d9ff9ef814cedf466f94ba27",
    "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
    "absolute_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
    "txt_url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q2-2025/part-001.html",
        "chars": 83790
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2025",
    "title": "Kvartalsrapport Q1 2025",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a0630e41971a7e7f83d3e62a07a7dd3b4",
    "date": "2025-04-24",
    "period": "2025-q1",
    "form_type": "interim-report",
    "report_key": "2025:q1",
    "filename": "XVIVO_Delarsrapport_Q1_2025.pdf",
    "text_chars": 70692,
    "sha256": "58b696e541849758b47240a3be059d9cee3d470c19393430a39a15701c5de5a0",
    "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
    "absolute_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
    "txt_url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q1-2025/part-001.html",
        "chars": 70692
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-arsredovisning-2024",
    "title": "Årsredovisning 2024",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a479f81637801444ef3fec443441821b6",
    "date": "2025-04-02",
    "period": "2024-annual",
    "form_type": "annual-report",
    "report_key": "2024:annual",
    "filename": "XVIVO_Perfusion_AB_publ_Arsredovisning_2024.pdf",
    "text_chars": 309968,
    "sha256": "e009304fe3af6debb56cf1237544516db5b42015773d9272b02295c98cd55975",
    "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-arsredovisning-2024",
    "absolute_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-arsredovisning-2024",
    "txt_url": "/company/xvivo-perfusion/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-arsredovisning-2024/part-001.html",
        "chars": 178215
      },
      {
        "number": 2,
        "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-arsredovisning-2024/part-002.html",
        "chars": 131751
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2024",
    "title": "Kvartalsrapport Q4 2024",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a3fca5cd2988e9f95e40dcea4b9ae30c1",
    "date": "2025-01-28",
    "period": "2024-q4",
    "form_type": "year-end-report",
    "report_key": "2024:q4",
    "filename": "XVIVO_Bokslutskommunike_2024.pdf",
    "text_chars": 98297,
    "sha256": "18d8631ba7e30d2b81ea8cbe5d327551e3a610d98a87d0f1098e0553a520d40c",
    "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
    "absolute_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
    "txt_url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q4-2024/part-001.html",
        "chars": 98297
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2024",
    "title": "Kvartalsrapport Q3 2024",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/aafd86ee6455d0f214bead4e7b87db27d",
    "date": "2024-10-24",
    "period": "2024-q3",
    "form_type": "interim-report",
    "report_key": "2024:q3",
    "filename": "XVIVO_Delarsrapport_Januari_September_2024.pdf",
    "text_chars": 93302,
    "sha256": "6d244769370a20ed82430da4bf230cb52faf47597c0a042d254b43e919d65117",
    "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
    "absolute_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
    "txt_url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q3-2024/part-001.html",
        "chars": 93302
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2024",
    "title": "Kvartalsrapport Q2 2024",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/ae4bc39452b8c18d57d41d1a3d79b4dd3",
    "date": "2024-07-12",
    "period": "2024-q2",
    "form_type": "interim-report",
    "report_key": "2024:q2",
    "filename": "XVIVO_Delarsrapport_Q2_2024.pdf",
    "text_chars": 84644,
    "sha256": "c8646a6f2eeaf79da17e0c576eb1caaa49ef7226b8b46765c02aa7700fada482",
    "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
    "absolute_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
    "txt_url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q2-2024/part-001.html",
        "chars": 84644
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2024",
    "title": "Kvartalsrapport Q1 2024",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/afd08b19f207c3c067419219657cee68a",
    "date": "2024-04-24",
    "period": "2024-q1",
    "form_type": "interim-report",
    "report_key": "2024:q1",
    "filename": "XVIVO_Delarsrapport_Q1_2024.pdf",
    "text_chars": 73866,
    "sha256": "07e7c535f884c16dcee0b372ced28af7741716c998b9b8288ffd6d6d277a0c87",
    "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q1-2024",
    "absolute_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q1-2024",
    "txt_url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q1-2024/part-001.html",
        "chars": 73866
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-arsredovisning-2023",
    "title": "Årsredovisning 2023",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/adb17d80609340e8198aeadcdb3edac22",
    "date": "2024-04-04",
    "period": "2023-annual",
    "form_type": "annual-report",
    "report_key": "2023:annual",
    "filename": "XVIVO_Perfusion_AB_publ_Arsredovisning_2023.pdf",
    "text_chars": 328330,
    "sha256": "a966b828525b8879f5bce518b9e132e61bbb641a3d838f80a85244b8ac8c5acb",
    "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-arsredovisning-2023",
    "absolute_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-arsredovisning-2023",
    "txt_url": "/company/xvivo-perfusion/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-arsredovisning-2023/part-001.html",
        "chars": 176290
      },
      {
        "number": 2,
        "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-arsredovisning-2023/part-002.html",
        "chars": 152038
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2023",
    "title": "Kvartalsrapport Q4 2023",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a9f7506bf556d77c16fc28778ffd31219",
    "date": "2024-01-25",
    "period": "2023-q4",
    "form_type": "year-end-report",
    "report_key": "2023:q4",
    "filename": "XVIVO_Bokslutskommunike_2023.pdf",
    "text_chars": 102592,
    "sha256": "0c2d8c4e7dfaee195a580c9dabbcf0996d49aa0f4fc6e7c5563dc388014a2c3a",
    "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q4-2023",
    "absolute_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q4-2023",
    "txt_url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q4-2023/part-001.html",
        "chars": 102592
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2023",
    "title": "Kvartalsrapport Q3 2023",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a945137115ed567efad38b5e038ff0c75",
    "date": "2023-10-24",
    "period": "2023-q3",
    "form_type": "interim-report",
    "report_key": "2023:q3",
    "filename": "XVIVO_Delarsrapport_Januari_September_2023.pdf",
    "text_chars": 97520,
    "sha256": "6f9acea7642de192e012480e7d1d576d625601d3911a15461a49342a64288a45",
    "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q3-2023",
    "absolute_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q3-2023",
    "txt_url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q3-2023/part-001.html",
        "chars": 97520
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2023",
    "title": "Kvartalsrapport Q2 2023",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a07f7d275af50fb575d75dd0872902212",
    "date": "2023-07-13",
    "period": "2023-q2",
    "form_type": "interim-report",
    "report_key": "2023:q2",
    "filename": "XVIVO_Delarsrapport_Januari_Juni_2023.pdf",
    "text_chars": 88874,
    "sha256": "a9fb480625eb2301c97255699c01b78794f8c9d63c2c0c9f534a23378ec8d359",
    "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q2-2023",
    "absolute_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q2-2023",
    "txt_url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q2-2023/part-001.html",
        "chars": 88874
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2023",
    "title": "Kvartalsrapport Q1 2023",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a01a8f1549d0c7ef8ac32bacf15691322",
    "date": "2023-04-24",
    "period": "2023-q1",
    "form_type": "interim-report",
    "report_key": "2023:q1",
    "filename": "XVIVO_Delarsrapport_Q1_2023.pdf",
    "text_chars": 71155,
    "sha256": "52cffa027d836b5446c9f546895c872a7b1d3b202caf8749688a45ae46a10345",
    "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q1-2023",
    "absolute_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q1-2023",
    "txt_url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q1-2023/part-001.html",
        "chars": 71155
      }
    ]
  },
  {
    "doc_id": "mfn-mfn-bolagssida-och-bolagsmetadata",
    "title": "MFN bolagssida och bolagsmetadata",
    "source": "MFN",
    "source_class": "mfn",
    "source_url": "https://mfn.se/all/a/xvivo-perfusion",
    "date": null,
    "period": null,
    "form_type": "company-page",
    "report_key": null,
    "filename": "company.txt",
    "text_chars": 13628,
    "sha256": "efd4a31f9f69198fa818c805ade7fb1fcfa565a9072c06b54968c5e9af68d0a1",
    "url": "/company/xvivo-perfusion/documents/mfn-mfn-bolagssida-och-bolagsmetadata",
    "absolute_url": "https://spela.port0.org/company/xvivo-perfusion/documents/mfn-mfn-bolagssida-och-bolagsmetadata",
    "txt_url": "/company/xvivo-perfusion/documents/mfn-mfn-bolagssida-och-bolagsmetadata/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/xvivo-perfusion/documents/mfn-mfn-bolagssida-och-bolagsmetadata/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/xvivo-perfusion/documents/mfn-mfn-bolagssida-och-bolagsmetadata/part-001.html",
        "chars": 13628
      }
    ]
  }
]